KPTI (Karyopharm Therapeutics Inc.) Enterprise Value-to-Revenue Coefficient

Official company branding of Karyopharm Therapeutics (KPTI)

Karyopharm Therapeutics (KPTI) enjoys high physician confidence due to the efficacy of XPOVIO in treating myeloma, which has enabled the brand to establish a unique class of SINE compounds. On GURU.Markets, the historical EV/Sales trend clearly links these achievements, with the most recent value recorded as 0.00. However, capital is currently under pressure due to debt obligations and declining sales volumes of the core product.

Karyopharm Therapeutics, Inc. (KPTI): EV/Sales Multiple from 11/23/2025 to 11/20/2026

Financial and market metric breakdowns for Karyopharm (KPTI)

- business market valuation indicators:
- cash balance and cash flow data:
Fundamental company valuation:Karyopharm Therapeutics, Inc. KPTI
Product sample of Karyopharm Therapeutics, Inc.

For the biotech sector, where Karyopharm Therapeutics (KPTI) minimizes capital expenditures through production outsourcing, this indicator becomes a key tool for assessing the market value of the business regardless of debt load. By analyzing the EV-to-total-revenue multiple, an investor compares the enterprise value with actual sales, allowing for an objective assessment of the company's lean operating model efficiency amid interest rate volatility.